论文部分内容阅读
目的研究批格列酮联合二甲双胍及炔雌醇环丙孕酮(达英-35)治疗多囊卵巢综合征临床效果。方法选取150例多囊卵巢综合征患者,随机分为二甲双胍组、二甲双胍+吡格列酮组和吡格列酮+二甲双胍+达英-35组各50例,比较3组多囊卵巢综合征患者治疗效果及不良反应变化差异。结果二甲双胍组治疗有效率为66.0%,吡格列酮+二甲双胍组治疗有效率为80.0%,吡格列酮+二甲双胍+达英-35组治疗有效率为92.0%,吡格列酮+二甲双胍+达英-35组与二甲双胍组、吡格列酮+二甲双胍组比较,差异有统计学意义(P<0.05);治疗期间3组患者均未有明显不良反应发生。结论吡格列酮+二甲双胍+达英-35治疗多囊卵巢综合征疗效显著,患者不良反应发生率低,值得临床推广应用。
Objective To study the clinical effect of glicaglitazone combined with metformin and ethinyl estradiol cyproterone (Darlene-35) in the treatment of polycystic ovary syndrome. Methods 150 patients with PCOS were randomly divided into metformin group, metformin plus pioglitazone group and pioglitazone plus metformin + up to -35 group and 50 patients respectively. The curative effect and adverse reactions in the patients with PCOS were compared difference. Results The effective rate of metformin group was 66.0%, that of pioglitazone + metformin group was 80.0%, that of pioglitazone + metformin + group of Ying-35 was 92.0%, that of pioglitazone + metformin + group of metformin was higher than that of metformin group, Pioglitazone + metformin group, the difference was statistically significant (P <0.05); no significant adverse reactions occurred in all three groups during the treatment. Conclusion The efficacy of pioglitazone + metformin + dyn-35 in the treatment of polycystic ovary syndrome is significant, and the incidence of adverse reactions in patients is low, which is worthy of clinical application.